Literature DB >> 26235624

In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector.

Eric Zinn1, Simon Pacouret1, Vadim Khaychuk1, Heikki T Turunen1, Livia S Carvalho1, Eva Andres-Mateos1, Samiksha Shah1, Rajani Shelke1, Anna C Maurer1, Eva Plovie1, Ru Xiao1, Luk H Vandenberghe2.   

Abstract

Adeno-associated virus (AAV) vectors have emerged as a gene-delivery platform with demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders. However, limitations of the current generation vectors often prevent broader application of AAV gene therapy. Efforts to engineer AAV vectors have been hampered by a limited understanding of the structure-function relationship of the complex multimeric icosahedral architecture of the particle. To develop additional reagents pertinent to further our insight into AAVs, we inferred evolutionary intermediates of the viral capsid using ancestral sequence reconstruction. In-silico-derived sequences were synthesized de novo and characterized for biological properties relevant to clinical applications. This effort led to the generation of nine functional putative ancestral AAVs and the identification of Anc80, the predicted ancestor of the widely studied AAV serotypes 1, 2, 8, and 9, as a highly potent in vivo gene therapy vector for targeting liver, muscle, and retina.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26235624      PMCID: PMC4536165          DOI: 10.1016/j.celrep.2015.07.019

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  54 in total

1.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

3.  Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Authors:  Brittney L Gurda; Christina Raupp; Ruth Popa-Wagner; Matthias Naumer; Norman H Olson; Robert Ng; Robert McKenna; Timothy S Baker; Jürgen A Kleinschmidt; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

4.  Phylogeny-aware gap placement prevents errors in sequence alignment and evolutionary analysis.

Authors:  Ari Löytynoja; Nick Goldman
Journal:  Science       Date:  2008-06-20       Impact factor: 47.728

5.  Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid.

Authors:  Christie L Bell; Brittney L Gurda; Kim Van Vliet; Mavis Agbandje-McKenna; James M Wilson
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

Review 6.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

7.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.

Authors:  Xuan Shen; Terry Storm; Mark A Kay
Journal:  Mol Ther       Date:  2007-08-28       Impact factor: 11.454

9.  Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.

Authors:  Wuping Li; Aravind Asokan; Zhijian Wu; Terry Van Dyke; Nina DiPrimio; Jarrod S Johnson; Lakshmanan Govindaswamy; Mavis Agbandje-McKenna; Stefan Leichtle; D Eugene Redmond; Thomas J McCown; Kimberly B Petermann; Norman E Sharpless; Richard J Samulski
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

10.  DNA shuffling of adeno-associated virus yields functionally diverse viral progeny.

Authors:  James T Koerber; Jae-Hyung Jang; David V Schaffer
Journal:  Mol Ther       Date:  2008-08-26       Impact factor: 11.454

View more
  108 in total

1.  Hearing in the mouse of Usher.

Authors:  John V Brigande
Journal:  Nat Biotechnol       Date:  2017-03-07       Impact factor: 54.908

Review 2.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

Review 4.  Gene therapy for hearing loss.

Authors:  Ryotaro Omichi; Seiji B Shibata; Cynthia C Morton; Richard J H Smith
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

5.  High-Throughput Quantification of In Vivo Adeno-Associated Virus Transduction with Barcoded Non-Coding RNAs.

Authors:  Meiyu Xu; Jia Li; Jun Xie; Ran He; Qin Su; Guangping Gao; Phillip W L Tai
Journal:  Hum Gene Ther       Date:  2019-06-17       Impact factor: 5.695

6.  CREATEd viruses go global.

Authors:  Keisuke Yonehara; Botond Roska
Journal:  Nat Neurosci       Date:  2017-07-26       Impact factor: 24.884

Review 7.  Toward the Optical Cochlear Implant.

Authors:  Tobias Dombrowski; Vladan Rankovic; Tobias Moser
Journal:  Cold Spring Harb Perspect Med       Date:  2019-08-01       Impact factor: 6.915

8.  AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations.

Authors:  Simon Pacouret; Mohammed Bouzelha; Rajani Shelke; Eva Andres-Mateos; Ru Xiao; Anna Maurer; Mathieu Mevel; Heikki Turunen; Trisha Barungi; Magalie Penaud-Budloo; Frédéric Broucque; Véronique Blouin; Philippe Moullier; Eduard Ayuso; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2017-04-17       Impact factor: 11.454

Review 9.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 10.  Systemic delivery of adeno-associated viral vectors.

Authors:  Dongsheng Duan
Journal:  Curr Opin Virol       Date:  2016-07-25       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.